NCT03193684View on ClinicalTrials.gov

Empagliflozin and Hepatic Glucose Metabolism

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 20, 2018

Primary Completion Date

January 30, 2023

Study Completion Date

January 30, 2024

Conditions
Hepatic Glucose Metabolism
Interventions
DRUG

Empagliflozin 25 MG

subjects will receive daily dose of 25mg of empagliflozin for 3 months

DRUG

Control

Placebo

Trial Locations (1)

78229

Diabetes Division, UTHSCSA, San Antonio

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT03193684 - Empagliflozin and Hepatic Glucose Metabolism | Biotech Hunter | Biotech Hunter